Objective, peer-reviewed reporting on therapeutic peptides, regulatory updates, clinical trial results, and scientific consensus. No hype. No product sales.
Articles tagged Tirzepatide.
A new ENDO 2026 wearable-data study found GLP-1 users lost weight but moved less. Alex Keane explains why steps, resistance training, and muscle protection now matter.
GLP-1 cancer risk is suddenly a mainstream question. Alex Keane explains what the newest studies suggest, what they do not prove, and why peptide biology matters.
Retatrutide search interest is rising alongside GLP-1 hype. Here is what the evidence says, what remains investigational, and why gray-market peptides are risky.
GLP-1 drugs and retatrutide are suddenly part of the knee osteoarthritis conversation. Here is what the peptide science says, and what remains unproven.
GLP-1 muscle loss is today’s peptide-health conversation because apitegromab, a myostatin-targeting antibody, just showed early evidence of preserving lean mass during tirzepatide weight loss.
No articles match that search.